MOBILion Systems Inc. Announces $60 Million Series C Financing Round Led by D1 Capital Partners to Expand Commercial Activities and Accelerate Product Development

MOBILion Systems Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. The round was led by D1 Capital Partners with the remaining funds contributed by existing investors aMoon, Agilent Technologies (NYSE:A), IP Group, Hostplus and Cultivation Capital.

The funding comes on the heels of the recent launch of MOBILion's first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE^®, which, as demonstrated in recent peer reviewed publications, addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE^® provides faster, easier and more complete analysis of multiple critical quality assays to accelerate biotherapeutic drug development and significantly enhance protein characterization capabilities that affect product quality, safety and efficacy. Proceeds will be used to scale the commercialization of MOBIE^® to deliver improved biologic therapeutic characterization to the broader biopharma industry and advance product development for expansion into bioprocessing and multiomic biomarker discovery markets.